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Introduction: Angiogenesis is fundamental for tumor development and
progression. Hence, anti-angiogenic drugs have been developed to target
VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs)
have been developed over the years and others are still under investigation,
each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of
the cardiac side-effects of each drug and the magnitude of their expression
and frequency can lead to a specific approach.
Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs
and the pathophysiological mechanisms leading to cardiotoxicity, followed by
close examination of the most important drugs individually. A literature
search was conducted on PubMed selecting review articles, original studies
and clinical trials, with a focus on Phase III studies.
Expert opinion: Side-effects on the cardiovascular system could lead both to
the worsening of general health status of cancer patients and to the discon-
tinuation of the cancer treatment affecting its efficacy. Cardiologists often
have to face new triggers of heart disease in these patients. They need a
specific approach, which must be carried out in cooperation with oncologists.
It must start before cancer treatment, continue during it and extend after
its completion.
Keywords: axitinib, cardio-oncology, cardiotoxicity, pazopanib, regorafenib, sorafenib,
sunitinib, tyrosine kinase inhibitors, vandetanib, VEGF
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1. Introduction
For many years cancer research has aimed to find new therapeutic options that could
go beyond, and substitute, the already existing chemotherapy drugs in tumor treat-
ment, so as to limit side-effects and overcome the edge of the treatment used. There-
fore, in the past years, new targeted drugs that have a specific molecular target have
been developed. Among the therapeutic agents which are now under development in
oncology, angiogenic process is one of the main targets. These anti-angiogenic
drugs act on the development of new blood vessels that furnish an adequate meta-
bolic contribution to the microenvironment, which is necessary for tumor growth
and its systemic spread [1]. In this review, we discuss the anti-angiogenic drugs target-
ing tyrosine kinase receptors approved by the FDA: sorafenib (2005), sunitinib
(2006), pazopanib (2009), vandetanib (2011), axitinib (2012) and regorafenib
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(2012). Besides, we discuss two other drugs which have not yet
been approved. These drugs are vatalanib and nintedanib
(Table 1).
2. Mechanism of action of anti-VEGFR
tyrosine kinase inhibitors
The angiogenic process starts on the basis of a balance in the
action of several regulatory molecules that could stimulate or
inhibit the growth. These regulatory molecules include:
VEGF, acidic fibroblast growth factor (FGF), basic FGF,
TGF-a, TGF-b, hepatocyte growth factor (HGF or scatter
factor), TNF-a, angiogenin, angiostatin, IL-8 and the angio-
poietins [2]. VEGF is a growth factor that acts specifically on
endothelial cells. It regulates their activity, being crucial in
angiogenesis both physiologically and pathologically. VEGF
can occur in various isoforms, including VEGF-A, VEGF-B,
VEGF-C and VEGF-D. VEGF-A is a proangiogenic factor
that plays important roles in cell migration, proliferation
and survival. Alternative splicing yields at least six isoforms
of VEGF-A, through a different incorporation of exons that
determine the degree of cell surface and extracellular matrix
association. These isoforms are respectively constituted by
121, 145, 165, 183, 189 and 206 amino acid residues. The
VEGF165 is the predominant form. These growth factors
bind to VEGF receptors on endothelial cells and promote
their proliferation, survival, migration and tube formation.
These isoforms in turn interact with receptor tyrosine kinases
(RTKs) that present three forms: VEGFR1, VEGFR2 and
VEGFR3. VEGF binds with higher affinity to VEGFR1
than to VEGFR2, the latter having a stronger tyrosine kinase
activity. Besides, VEGFR2 is widely assumed to be the medi-
ator of the pro-angiogenic activities of VEGF. VEGFR3 is
involved in lymphangiogenesis and does not bind VEGF-A
[2-4]. Nevertheless, VEGFR1 and VEGFR2 could crosstalk
inter- and intra-molecularly. VEGF binds to the VEGFR,
leading to receptor dimerization and subsequent autophos-
phorylation of this complex. The phosphorylated receptor
interacts with a variety of cytoplasmic signaling molecules,
leading to signal transduction and eventually angiogenesis.
The classical Ras/Erk and PI3K/Akt-dependent pathways are
involved in the signaling activated by the VEGF-VEGFR net-
work, thus leading to the proliferation and survival of
endothelial progenitors [4]. There are three classes of PI3Ks
grouped according to structure and function. Class IA
PI3Ks are activated by growth factor (such as VEGF) stimula-
tion through RTKs. The regulatory subunit, p85, directly
binds to phosphotyrosine residues on RTKs and/or adaptors.
This bond relieves the intermolecular inhibition of the cata-
lytic subunit, p110, by p85 and localizes PI3K to the plasma
membrane where resides its substrate, phosphatidylinositol
4,5-bisphosphate (PI[4,5]P2). PI3K can also be stimulated
by activated Ras. Additionally, the p110b catalytic subunit
can be activated by G-protein coupled receptors. PI3K phos-
phorylates PIP2 (Phosphatidylinositol 4,5-bisphosphate) on
the 3’OH position to produce PI(3,4,5)P3. PI(3,4,5)
P3 brings two PH domain-containing serine/threonine kin-
ases, phosphoinositide-dependent kinase 1 (PDK1) and
AKT, into close proximity. PDK1 activates AKT by phos-
phorylating it at threonine 308. PI3K-AKT signaling pro-
motes cell growth and survival by several mechanisms. AKT
promotes cell survival by inhibiting proapoptotic Bcl-2 family
members. AKT also impedes negative regulation of the tran-
scription factor NF-kB, leading to increased transcription of
antiapoptotic and prosurvival genes. Phosphorylation of
Mdm2 by AKT antagonizes p53-mediated apoptosis [5]. The
recognition of the VEGF pathway as a key regulator of angio-
genesis has led to the development of several VEGF-targeted
agents that include: neutralizing antibodies to VEGF or
VEGFRs, soluble VEGF receptors or receptor hybrids and
tyrosine kinase inhibitors (TKIs) with selectivity for VEGFRs.
TKIs are more selective rather than specific for a particular
kinase, in relation to their course of action at the ATP-
binding pocket. So, TKIs are designed to target VEGF recep-
tors, but they are actually ‘multi-kinase’ inhibitors. For exam-
ple, sorafenib and sunitinib also have significant activity
against the Raf, platelet-derived growth factor receptor
(PDGFRb), fibroblast growth factor receptor (FGFR),
FLT3, KIT and FMS (also known as CSF1R) receptors.
Therefore, it is likely that some of the clinical activity can be
attributed to activity on other tyrosine kinase receptors. Par-
ticularly, some VEGFR-targeted TKIs significantly inhibit
Article highlights.
. The angiogenic process is a physiological one based on
the equilibrium between pro-angiogenic (such as VEGF,
which regulates endothelial cells) and anti-angiogenic
molecules.
. VEGF-A is the main isoform, which is involved in cell
migration, proliferation and survival.
. VEGF signaling suppression, through the impairment of
nitric oxide synthesis, determines endothelial dysfunction
and vasoconstriction, producing a state of non-
perfusion, which are reasons for hypertension and
microvascular rarefaction.
. Platelet-derived growth factor receptor-b is important
for adaptation to afterload stress in cardiomyocytes;
indeed its suppression determines a reduction in cardiac
capillary density and local tissue hypoxia, playing a role
in the worsening of ventricular hypertrophy, ventricular
dilation and heart failure.
. Each tyrosine kinase inhibitor exerts different
cardiotoxicity (there are two types of toxicity: on-target
toxicity, also called target-related, and off-target toxicity)
on the heart and the cardiovascular system through
side-effects that have different magnitudes of expression
and frequencies.
. The recent and developing drugs seem to produce less
cardiotoxicity compared to the older molecules, and this
applies especially to nintedanib.
This box summarizes key points contained in the article.
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the activity of PDGFRs, and this leads to a dual attack on the
vasculature (VEGFR on endothelial cells and PDGFR on
pericytes). For this reason, it shows, in preclinical studies, a
greater efficacy than inhibiting a single receptor family [6].
3. Pathophysiological mechanisms of
cardiotoxicity of anti-angiogenic drugs
TKIs inhibit TK receptors both in cancer and normal cells.
Therefore, this action on normal tissues explains their side-
effects. The most common side-effects include diarrhea and
skin rash. Although cardiac toxicity is less common, it is
more serious and difficult to diagnose in early stages. Cardiac
toxic effects of TKIs include asymptomatic QT prolongation,
reduction in left ventricular ejection fraction (LVEF), symp-
tomatic congestive heart failure (CHF), hypertension, acute
coronary syndromes (ACS) and myocardial infarction (MI).
Sudden death has also been associated with these drugs. Not
all TKIs exert the same toxicity on the heart muscle and the
cardiovascular system. The level of expression of certain TK
receptors in the cardiomyocytes does not correlate with the
toxicity induced by their related inhibitors; rather the func-
tion of a specific TK receptor constitutes the determining fac-
tor for the cardiac effects of its inhibition. The exact rates of
cardiotoxicity are not well known yet.
The inhibition of the ‘key’ kinases that drive tumorigenesis
could potentially compromise the survival of cardiomyocytes,
leading to the cardiotoxicity exerted by TKIs. This toxicity
can be distinguished into two types: 1) on-target toxicity,
also known as mechanism-based or target-related, in which
the kinase that is targeted in the cancer also provides an
important maintenance function in the heart and vasculature.
Thus, the inhibition leads to adverse consequences in the
heart. 2) Off-target toxicity: a kinase that was not intended
to be inhibited by a drug is inhibited, and if this kinase plays
a key role in the heart its inhibition will lead to cardiotoxicity.
Off-target toxicity is inherently related to the limited selectiv-
ity of most TKIs. In fact, cardiotoxicity results from the non-
specific inhibition of multiple kinases on signaling pathways
important for maintaining ventricular function. The inhibi-
tion by sunitinib on AMPK (AMP-activated protein kinase)
is an example of off-target toxicity. This kinase plays key roles
in maintaining metabolic homeostasis in the heart, especially
in the setting of energy stress. AMPK is activated when energy
stores drop in the cardiomyocyte. It leads to increased energy
generation and decreased energy utilization, but it is not acti-
vated in the energy-stressed cardiomyocytes. AMPK activity is
reduced in sunitinib-treated heart models and in cultured car-
diomyocytes. This drug causes cell damage, so that there is a
myocardial cell loss, or inhibits normal repair processes [7-
13]. It has to be specified that AMPK inhibition is not the
only one responsible for cardiotoxicity and it could be only
partial. Indeed, metformin, which is able to activate AMPK
in myocytes, did not defend them from sunitinib-induced
toxicity [14].
The inhibition of VEGF signaling by TKIs can cause
hypertension, and this is one of the main cardiac toxic effects
(Figure 1). VEGF, through VEGFR2, has a hypotensive effect.
In normal cells, functional VEGFR2 triggers PI3K, through
Src, and phospholipase C (PLC). PI3K converts PIP2 to
PIP3. The latter acts on PD1K, which initiates Akt. So in
the end, Akt stimulates the endothelial nitric oxide synthase
Table 1. Angiogenesis tyrosine kinase inhibitors: year of FDA approval, labels, pivotal trials.
Drug FDA approval
(year)
Approved for Phase III trials Authors
Sorafenib 2005 Hepatocellular carcinoma
Child-Pugh A or B
SHARP trial
Asia-Pacific trial (NCT00492752)
Llovet et al. (2008) [32]
Cheng et al. (2009) [36]
mRCC TARGET trial Escudier B et al. (2009) [34]
Sunitinib 2006 Metastatic GIST NCT00075218 Demetri et al. (2006) [39]
mRCC NCT00098657 and NCT00083889 Motzer et al. (2007) [40]
Pancreatic neuroendocrine
tumors
NCT00428597 Raymond et al. (2011) [41]
Pazopanib 2009 Relapsed or refractory RCCs VEG105192 (NCT00334282) Sternberg et al. (2010) [49]
Soft-tissue sarcomas PALETTE trial van der Graaf et al. (2012) [51]
Vandetanib 2011 Metastatic medullary thyroid
carcinoma
NCT00410761 Wells et al. (2012) [57]
Axitinib 2012 Second-line treatment of
patients with mRCC
AXIS trial
NCT00920816
Rini et al. (2011) [62]
Hutson et al. (2013) [65]
Regorafenib 2012 Advanced GIST GRID trial Demetri et al. (2013) [70]
Previously treated metastatic
colorectal cancer
CORRECT trial Grothey et al. (2013) [71]
Vatalanib Not approved yet -- CONFIRM 1 trial (NCT00056459)
CONFIRM 2 trial
Hecht et al. (2011) [75]
Van Cutsem et al. (2011) [76]
Nintedanib Not approved yet -- LUME-Lung 1 Reck et al. (2014) [83]
GIST: Gastrointestinal stromal tumor; mRCC: Metastatic renal cell carcinoma.
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(eNOS). On the other hand, activated PLC transforms PIP2
in the second messengers, inositol trisphosphate (IP3) and
diacylglycerol. The first of these two products leads to the
entry of Ca2+ ions within the cell. The enhanced concentra-
tion of calcium starts eNOS activity. Hence, both of these
two pathways lead to the upregulation of eNOS. eNOS deter-
mines the production of nitric oxide (NO), which regulates
vascular relaxation. In fact, NO activates guanylyl cyclase
that raises cGMP levels, determining vasodilation, reducing
smooth muscle cells growth and platelet aggregation. There-
fore, the elimination of constitutive baseline VEGF signaling
induces endothelial dysfunction and vasoconstriction. These
events occur because the activity of the inducible NO synthe-
sis is compromised. These two events create a state of non-
perfusion. Hence, these are the bases for hypertension and
microvascular rarefaction, which means the extinction of the
small blood vessels that constitute the microcirculation. In
fact, the depletion of VEGF-A release, in protracted hypoxic
conditions, is considered an important factor, which contrib-
utes to decompensated heart failure. In the advanced stage of
the disease, VEGF-A reduction has been connected to unbal-
anced microvascular growth and reduced capillary density.
VEGF is upregulated during hypertension, providing com-
pensatory responses. Anti-VEGF therapy suppressing it deter-
mines a weaker compensatory role. Hypertension is associated
with the development of left ventricular hypertrophy, which is
a strong independent predictor of cardiovascular morbidity
and mortality. Hypertensive cardiac remodeling results in car-
diomyocyte hypertrophy outgrowing capillary expansion. The
decline in microvascular density leads to hypertension-
associated cardiovascular events. Animal models with
cardiomyocyte-specific deletion of the VEGF gene had fewer
coronary microvessels, thinned ventricular walls and
depressed contractile function. Induced hypertrophy in
VEGF-deficient mice expedite the transition from compensa-
tory hypertrophy to failure. In other animal models, data
enlightened that supplementation of VEGF, during pro-
longed pressure overload, preserved the contractile function.
However, it has to be specified that the decrease in microvas-
cular density is not the only reason for cardiovascular events.
Other important factors play a key role in the development
of load-induced cardiac pathologies, which are abnormal
Ca2+ handling in cardiomyocytes, a shift in energy metabo-
lism and accumulation of interstitial fibrosis.
Some studies demonstrated that another participant in the
TKI-induced hypertension could be endothelin (ET). The
administration of sunitinib showed an increase in circulating
ET-1 levels, prompting that the ET pathway plays an impor-
tant role in sunitinib-induced increase of blood pressure.
ET-1 carries out a vasoconstrictor effect through the activa-
tion of NADPH (which is the reduced form of nicotinamide
adenine dinucleotide phosphate) oxidase and the generation
VEGF-A
VEGFR2
PIP2
PIP2
PIP3
IP3
PD1K
PI3K
Src
Ca2+
Akt
eNOS
NO
DAG
GC
GTP
Gene expression
Cell proliferation
cGMP
Hypertension
Cell survival Nucleus
PLC
ERK 1/2
PKC
RAS
MEK 1/2
RAF
•  Endothelial dysfunction
•  Vasoconstriction
VEGFR1 VEGFR3
TKIs
Endothelial cell
VEGF-B
VEGF-C VEGF-D
Figure 1. The effects of angiogenesis tyrosine kinase inhibitors on hypertension. The block of VEGFR function induces changes
in eNOS pathway with consequences on vasoconstriction and endothelial dysfunction and subsequently on hypertension.
DAG: Diacylglycerol; eNOS: Endothelial nitric oxide synthase; PLC: Phospholipase C; TKIs: Tyrosine kinase inhibitors.
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of reactive oxygen species. Vasoconstriction determines hyper-
tension, which has also been related to an increase in reactive
oxygen species. Besides, ET-1 has been shown to promote
angiogenesis in cancer. Therefore, the use of ET-1 receptor
antagonists could be important for treatment. Studies in ani-
mals demonstrated that the coadministration of an
ET-1 receptor antagonist with an RTKI limited blood
pressure enhancement.
The deletion of the PDGFR-b gene in cardiomyocytes
causes in models next to afterload stress a worsening of ven-
tricular hypertrophy, ventricular dilation and heart failure,
demonstrating how it is crucial for adaptation to afterload
stress. It leads also to a reduction in cardiac capillary density
and evidence of local tissue hypoxia. As regards heart failure,
another main cardiac toxic effect, an hypothesis has been pro-
posed to explain how anti-angiogenic drug treatment can lead
to it. This hypothesis considers two aspects. The first one is
the development of hypertension, which leads to afterload
stress on the heart. Normally, the heart is able to adapt to
afterload stress through compensatory mechanisms, but the
inhibition of PDGFR-b, determined by anti-angiogenic
TKIs, inhibits cardiac adaptation to afterload stress. Hence,
it causes heart failure (Figure 2) [15-23]. Common side-effects
are peripheral edema, an indicator of cardiac dysfunction,
and symptoms like fatigue and dyspnea that could also be
attributed to the disease itself or they could be associated
with other conditions [9]. If on one hand, these studies on ani-
mal models showed the role of the PDGFR-b in
cardiomyocytes, on the other hand the recent study by Chin-
talgattu et al. revealed that the pericyte is the principal cell
involved in coronary microvascular abnormalities and cardiac
dysfunction caused by sunitinib. They showed that sunitinib-
induced cardiotoxicity is linked to a decrease of coronary
microvascular pericytes, which determines changes in the cor-
onary microvasculature. Besides, they disclosed that the effect
of sunitinib is specifically direct on pericytes of the cardiac
muscle [24].
Among the main cardiac side-effects linked to TKIs are
thromboembolic events. In normal conditions, VEGF-
receptor signaling determines, in endothelial cells, an increase
of the prosurvival factor Bcl-2 and modulation of the MAPK
pathway, which is involved in a variety of cellular functions.
Bcl-xL is also an anti-apoptotic cell-survival factor. In endo-
thelial cells, it up-regulates VEGF-A production, and in plate-
lets, it is a major determinant of the life span. VEGF-
A--induced signaling, through VEGFR2, directly regulates
the junctional machinery in the intercellular gaps. VEGF-A
alters the endothelial-cell phenotype by increasing vascular
permeability, up-regulating expression of urokinase, tissue
plasminogen activator and the vascular cell adhesion mole-
cule. The cytoplasmic domain of VEGFR2 is part of a macro-
molecular complex. Shear stress enhances the formation of
this complex, thereby converting the adherens junction into
a mechanical transducer that initiates ‘outside--inside’ signal-
ing. Megakaryocytes and platelets contain the three major iso-
forms of VEGF-A -- VEGF121, VEGF165 and VEGF189
Afterload
stress
Cardiac adaptation
to afterload stress
VEGF-A
Hypertension
Heart failure
VEGFR
Endothelial cell
TKIs
Cardiomyocyte
PDGFR
PDGF
• Ventricular hypertrophy
• Ventricular dilatation
• Reduction in cardiac capillary
density
• Local tissue hypoxia
Figure 2. The role of the inhibition of main angiogenesis mediators, VEGFR and PDGFR, in the development of heart failure
through afterload stress.
PDGFR: Platelet-derived growth factor receptor; TKIs: Tyrosine kinase inhibitors.
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-- that are released after exposure to thrombin. VEGF secreted
by one or more cells, both in a paracrine and in an autocrine
way, activates VEGFR2, inducing its phosphorylation and
activation. The autocrine loop keeps vascular permeability sta-
bilizing the complex for the normal steady-state of the endo-
thelial function, while the paracrine pathway seems to play a
key role in promoting vascular permeability in the non-steady
states, such as inflammation and disassembling the complex.
Paracrine stimulation is necessary for vasculogenesis in the
angiogenesis of cancer or inflammation. Paracrine VEGF-A,
delivered to the vascular lining by platelets and other cells,
increases endothelial cell production of Bcl-2, and platelet-
activating factor, a phospholipid pro-inflammatory mediator,
induces expression of VEGF-A by endothelial cells. Another
contributor to microvascular stability is Bcl-xL. When Bcl-xL
and Bcl-2 are decreased, due to a reduction in VEGF levels dur-
ing anti-VEGF drug treatment, there is an imbalance between
cell survival and apoptosis. Endothelial cell apoptosis leads to
an exposure of the subendothelial membrane that activates
the coagulation cascade. This event promotes thromboembolic
events. Besides, VEGF released from platelet upregulates com-
ponents of the fibrinolytic system, and so anti-VEGF drugs
have an adverse effect on this mechanism [25-30].
4. Drugs formerly approved for cancer
treatment
4.1 Sorafenib
Sorafenib is a small molecule, an oral inhibitor of multiple
kinases that are present in tumor cells and tumor blood ves-
sels. It potently inhibits several of both serine/threonine and
tyrosine kinases including VEGFR2 and VEGFR3, PDGFRa
and PDGFRb, c-KIT, FLT3, RAF1 (v-raf-1 murine leukemia
viral oncogene homolog 1) and BRAF kinases (v-raf murine
sarcoma viral oncogene homolog B1), including BRAFV600E.
It is currently registered for the treatment of advanced pri-
mary hepatocellular carcinoma (HCC) Child-Pugh A or B
and advanced/metastatic renal cell carcinoma (mRCC). This
drug is generally well tolerated. It has several side-effects,
including cardiotoxicity. It is associated with cardiac ischemia
or infarction and hypertension [31]. In sorafenib-treated
patients, a higher incidence of hypertension, usually mild-
to-moderate, has been observed. Besides, it occurs earlier
than the other drugs, but on the other hand, it responds to
standard anti-hypertensive therapy.
Sorafenib was studied in advanced HCC by Llovet et al. in
a multicenter, randomized, double-blind, placebo-controlled,
Phase III trial. This trial was conducted at 121 centers in
21 countries in Europe, North America, South America and
Australasia. The authors enlisted 602 patients with advanced
HCC who had not received previous systemic treatment.
Among the sorafenib-treated patients (n = 297), any grade
hypertension was present in 5%. Drug-related grade 3 hyper-
tension was 2%, while there was no drug-related grade
4 hypertension. Cardiac ischemia or infarction was revealed,
respectively, in 3% and 1% of patients [32,33].
In a Phase III study, sorafenib was administered in pre-
treated patients affected by mRCC. The incidence of all-grade
hypertension was 17% in comparison with the placebo group
in which it was 2%. Grade 3 and grade 4 hypertension were
recorded in 4% of the sorafenib-treated group versus 1% in
placebo. Similar results were achieved in the expanded access
program in North America, in which about 2,504 patients
were enrolled. The incidence of all-grade hypertension was
12%, while grade 3 was present in 5%. Comparable results
have also been obtained in a Phase III, randomized, double-
blind, placebo-controlled trial, in which the authors analyzed
the use of sorafenib in patients affected by HCC. Besides, it
has been demonstrated that sorafenib determines a prolonga-
tion of the QT/QTc interval. This can lead to an increased
risk of ventricular arrhythmias [34-36]. Retrospective analyses
suggest that the development of hypertension, especially grade
moderate-to-severe, can be associated with a greater efficacy of
anti-angiogenic drugs. Ravaud et al. studied 93 patients eval-
uating the possible relationship between the onset of hyper-
tension and the drug efficacy treating them with sunitinib,
sorafenib and bevacizumab as first, second and third line for
mRCC. It was shown that among patients who developed
hypertension of grade 2 or higher, 88% had clinical benefit.
Besides, 53% of these patients maintained the clinical benefit
for a period ‡ 6 months [37].
Sorafenib treatment can determine an increased risk of
developing heart disease. Escudier et al., in their Phase III
trial, in patients with mRCC, noticed that the incidence of
heart attack or cardiac ischemia occurring during treatment
was 4.9% in the sorafenib-treated group, while it was 1.4%
in the placebo group. The incidence of CHF developed in
patients with mRCC treated with sorafenib was 1.7% versus
0.7% in the placebo group [34]. Instead, in the expanded
access program in North America, these type of cardiac events
were not documented [35]. Cheng et al., in their Phase III
study, in patients with advanced HCC, observed that the inci-
dence of heart attack or cardiac ischemia occurring during
treatment was 2.7% in sorafenib-treated patients and 1.3%
in the placebo-treated group. As regards the CHF, they had
different results, if compared with the other studies, because
they reported lesser events in sorafenib-treated patients
(0.9%) than the placebo-treated group (1.1%) [36].
Finally, in a meta-analysis that included over 10,000
patients, the incidence of arterial thromboembolic events
(ATEs) was analyzed. It was 1.7% for sorafenib-treated
patients. The relative risk (RR) of ATEs for TKI in compari-
son with controls was of 3.03. RR for sorafenib was 3.1, and it
was 2.39 for sunitinib [38].
4.2 Sunitinib
Sunitinib is a small molecule TKI. It inhibits mutated or over-
expressed kinases in cancer cells. It acts on a number of
growth factor receptors regulating both tumor cell
G. Bronte et al.
6 Expert Opin. Drug Saf. (2014) 14(2)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
Sa
f. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
93
.1
49
.1
40
.1
84
 o
n 
12
/1
3/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
proliferation/survival and tumor angiogenesis including
VEGFRs 1 -- 3, PDGFRa and PDGFRb, c-KIT, FMS-like
tyrosine kinase-3 (FLT3), CFS-1 receptor (CSF1R) and the
product of the human RET gene (RET). Currently, sunitinib
is registered for the treatment of metastatic and unresectable
gastrointestinal stromal tumor (GIST) [39], mRCC [40] and
unresectable or metastatic well-differentiated pancreatic neu-
roendocrine tumors [41]. It is generally well tolerated. It has
various side-effects, including cardiotoxicity [39,40,42]. Hyper-
tension is the most common cardiovascular adverse event
among sunitinib-treated patients. The rate and severity of
hypertension vary according to the definitions of hypertension
used and the population studied. In a meta-analysis including
13 clinical trials and a total of 4,999 patients, the incidence of
all-grade hypertension was 21.6%. The incidence of hyperten-
sion warranting the addition or adjustment to dosing of more
than one medication (NCI grade 3 or grade 4) was 6.8%. The
RR of grade 3 or grade 4 hypertension using sunitinib com-
pared to placebo was 23. Rini et al. using less strict criteria
found that 81% of patients with mRCC treated with suniti-
nib developed systolic blood pressure higher than
140 mmHg and 67% developed diastolic blood pressure
higher than 90 mmHg [43].
This drug, more than the other TKIs, can cause left ventric-
ular dysfunction. Schmidinger et al. performed an observa-
tional study of mRCC patients treated with either sorafenib
or sunitinib. They found that about one-third of the cohort
developed a cardiac event, defined as increased cardiac
enzymes, symptomatic arrhythmia requiring treatment, new
left ventricular dysfunction or ACS. About 10% of the cohort
required intermediate or intensive care admission [16].
Chu et al. conducted a review focusing on cardiac adverse
events in 75 patients with imatinib-resistant, metastatic
GIST treated with sunitinib, as part of an early Phase I/II clin-
ical trial. The 11% of patients treated with sunitinib, devel-
oped cardiac adverse events (e.g., CHF, MI or cardiac
death). The most common event was NYHA class III -- IV
CHF (8%). The treatment with the FDA-approved dosage
showed a steady decrease in LVEF ‡ 15% of the EF. Of
36 patients, 4 developed either CHF or LVEF decline
of ‡ 20% to an EF < 50%. Sunitinib also induced significant
blood pressure elevations; approximately 47% of the patients
developed hypertension > 150/100 mmHg. Grade 3 hyperten-
sion occurred in 17% of patients [44]. In an observational,
single-center study, a total of 86 patients was treated with
either sunitinib or sorafenib. A total of 74 patients were eligi-
ble for assessment of cardiotoxicity during TKI treatment.
Among these patients, 25 (33.8%) experienced a cardiac
event, 11 patients among sunitinib-treated and 14 among
sorafenib-treated. The 40.5% had ECG changes including
rhythm changes, conduction disturbances, axis change, QRS
amplitude changes, ST segment depression and elevation,
T wave changes and QT prolongation, 18% of these were
symptomatic. Of 25 patients having cardiac events, 13 pre-
sented typical clinical symptoms, such as angina, dyspnea
and dizziness; 7 patients (9.4%) were seriously compromised
and required intermediate care or intensive care admission.
A total of 22 patients underwent echocardiograms at the
event, and 10 of them were abnormal. Abnormalities included
reduced LVEF in 9 patients, regional contractile dysfunctions
in 7 and relaxation disturbances greater than grade 1 and peri-
cardial effusion in 1 patient each. The median duration of
TKI treatment on event occurrence was 8 weeks (ranging
from 2 to 48 weeks). In all these studies, all patients recovered
after cardiovascular management (e.g., medication, coronary
angiography, pacemaker implantation and heart surgery)
and were considered eligible for TKI continuation. Statisti-
cally, there was no significant survival difference between
patients who experienced a cardiac event and those who did
not experience a cardiac event. A noteworthy aspect is the
high percentage of patients with increased cardiac biomarkers,
such as creatine kinase myocardial band(CK-MB) and tropo-
nins, in the treatment group. Indeed, among the sunitinib-
treated patients, 54.5% had abnormal CK-MB and troponin.
An increased CK-MB was seen in 78.6% patients treated with
sorafenib, while an abnormal troponin was seen in 21.4% [45].
4.3 Pazopanib
Pazopanib is an orally assumed multitarget angiogenesis
inhibitor. It targets VEGF-1, VEGF-2 and VEGF-3 recep-
tors, PDGF-a and PDGF-b receptors, and c-KIT. It is used
in the treatment of relapsed or refractory RCCs [46] and
soft-tissue sarcomas. Recent Phase II and Phase III trials
highlighted a possible use of this drug in the treatment of
selected epithelial ovarian cancer patients [47]. Qi et al. in a
meta-analysis showed that the average incidence of all-grade
hypertension among patients receiving pazopanib was
35.9%. High-grade (grade 3 or grade 4) hypertension was
associated with significant morbidity and subsequent dose
reduction or discontinuation of pazopanib treatment. The tri-
als reported an average incidence of high-grade hypertension
among patients receiving pazopanib of 6.5% [48].
In a trial by Sternberg et al., the authors showed that arte-
rial thrombotic events occurred in 3% of pazopanib-treated
patients, among these MI/ischemia 2%, cerebrovascular
accident < 1% and transient ischemic attack < 1% compared
with the placebo-arm, in which there were none [49].
Pazopanib can also induce electrocardiographic changes.
QT-prolongation and torsade de pointes, though rare, are
serious adverse event due to pazopanib therapy. Less than
2% of patients can have a prolonged QT interval while receiv-
ing pazopanib. Due to the gravity of this event, baseline and
periodic electrocardiograms and electrolyte monitoring
should be carried out. For this reason, an oncologist should
pay more attention when pazopanib is used in patients with
a history of QT prolongation or if they are using any other
medication that may affect the QT interval [50].
The PALETTE trial studied pazopanib compared to pla-
cebo in angiogenesis inhibitor-naive patients with metastatic
soft-tissue sarcoma, who progressed despite previous standard
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chemotherapy. In this study, fatigue and hypertension were
among the most common adverse effects, with a G3 -- 4 tox-
icity rate of 13 and 7%, respectively. LVEF dropped in
16 patients in the pazopanib group, compared to 3 in the pla-
cebo group, during or after treatment. Among these
16 patients, 3 were symptomatic. However, LVEF had
improved in 8 patients. Among these, 5 continued pazopanib
and 3 discontinued for other reasons [51].
4.4 Vandetanib
Vandetanib (ZD6474) is an orally active small molecule TKI.
It acts against the VEGFR2. It also has inhibitory activity at
sub-micromolar concentrations against VEGFR3, the EGFR,
REarranged during Transfection (RET) tyrosine kinase, while
it acts on VEGFR1 and PDGFRb at micromolar concentra-
tions. This drug has been approved for the treatment of adult
patients with unresectable, locally advanced or metastatic med-
ullary thyroid carcinoma [52-55]. Vandetanib is tolerable at
doses of 300 mg or less. Wells et al. studied 331 patients
with locally advanced or metastatic medullary thyroid cancer
in a randomized, double-blind, Phase III trial. Among the
231 vandetanib-treated patients, any grade hypertension
occurred in 32% and grade 3 or higher hypertension occurred
in 9%. Asthenia of any grade arose in 14%, while grade 3 or
higher was seen in 3%. Another adverse event was dyspnea,
grade 3 or more, which was present in only 1%. QTc
prolongation required dose reduction in 35% of the
vandetanib-treated patients. About 18 patients (8%) devel-
oped protocol-defined QTc prolongation, grade 3 or higher,
but there were no reports of torsades de pointes. Any grade
QTc prolongation arose in 33 patients (14%). Among these
cardiac adverse events, QTc prolongation is a noteworthy
adverse effect. It has been proposed that potassium andmagne-
sium deficiency, which is possibly secondary to diarrhea, have
a role in its onset. The only adverse event leading to discontin-
uation of vandetanib was asthenia (1.7%). Five patients in the
vandetanib arm experienced adverse events leading to death
during the randomized phase; among these events there was
respiratory arrest, respiratory failure, arrhythmia and acute car-
diac failure in 1 patient [56,57]. Approximately similar results
were obtained by Leboulleux et al. in a randomized, double-
blind, Phase II trial. Any grade hypertension occurred in
34% of the vandetanib-treated patients. Any grade asthenia
came about in 26%, while grade ‡ 3 asthenia in 7%. Any grade
QTc prolongation was present in 23%, while grade ‡ 3 QTc
prolongation in 14%. Grade ‡ 3 dyspnea ensued in 3%.
Among the most common adverse events leading to discontin-
uation of vandetanib was QTc prolongation in 5 patients
(7%). They noted no cardiac complications linked to the pro-
longation of the QTc [58].
These data were analyzed together with other trials in a
meta-analysis by Qi et al. They included a total of 11 trials
with 3,154 patients affected by metastatic thyroid cancer
(MTC), NSCLC and other malignancies. The average inci-
dence of all-grade hypertension among patients receiving
vandetanib was 24.2%. Among the 11 trials, 8 reported a
mean incidence of 6.4% for high grade hypertension. The
mean all-grade and high grade incidences of hypertension in
patients with non-MTC/NSCLC tumors were 15.4 and
3.4%, respectively. Besides, the incidence about all-grade
and high grade hypertension in non-MTC/NSCLC tumors
were lower than NSCLC, in which it was 21.8% for all-grade
hypertension and 7.6% for high grade hypertension and
MTC. There was a significant difference between MTC and
NSCLC in terms of the incidence of vandetanib-associated
all-grade hypertension (RR 1.48), but not high grade hyper-
tension. Finally, vandetanib was associated with a significantly
increased risk of all-grade hypertension in comparison with
non-MTC/NSCLC tumors, but not high grade hyperten-
sion [59]. In a meta-analysis by Zang et al., the authors ana-
lyzed the incidence and risk of QTc interval prolongation
by vandetanib in the cancer patient. This meta-analysis was
based on 9 trials and included 2,188 patients. They showed
that the overall incidence of all-grade and high-grade QTc
interval prolongation was 16.4% and 3.7%, respectively,
among patients with non-thyroid cancer, and 18.0% and
12.0%, respectively, among patients with thyroid cancer. If
compared with the incidence of prolonged QTc interval
determined by other drugs, the incidence of all-grade QTc
interval prolongation associated with vandetanib is moderate.
This is an important aspect because QTc interval prolonga-
tion is one of the most important risk factors that induce
life-threatening consequence [60].
4.5 Axitinib
Axitinib is a third-generation VEGFR inhibitor. It is highly
selective and very potent for VEGFR1 -- 3. It has been
approved for use in the second-line treatment of patients
with metastatic RCC after failure of prior treatment with
sunitinib or a cytokine [61]. It has been studied in the AXIS
trial (Phase III), in which axitinib was compared to sorafenib.
The most common adverse events leading to discontinuation
in the axitinib group were fatigue (1%; 4) and transient ische-
mic attack (< 1%; 3). The most frequent cardiovascular
adverse event associated with axitinib was hypertension,
occurring in > 30% of patients. Indeed, all-grade hyperten-
sion showed a frequency of 40%, while grade 3 or higher
had a frequency of 16%. However, this study had several
important limitations; mostly it was not a blinded trial. Fur-
ther data revealed that diastolic blood pressure of 90 mmHg
or higher during study can help predict axitinib efficacy in
patients with solid tumors, including RCC [62,63]. In a meta-
analysis by Qi et al., the authors identified ten studies, includ-
ing two Phase III trials and eight Phase II trials, for a total of
1,908 patients. The underlying malignancies for these trials
included metastatic RCC, metastatic melanoma, metastatic
breast cancer, advanced NSCLC, pancreatic cancer and all
histological subtypes of advanced thyroid cancer. In each of
these trials, hypertension was not described as a pre-existing
condition. The mean incidence of all-grade hypertension
G. Bronte et al.
8 Expert Opin. Drug Saf. (2014) 14(2)
Ex
pe
rt 
O
pi
n.
 D
ru
g 
Sa
f. 
D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
93
.1
49
.1
40
.1
84
 o
n 
12
/1
3/
14
Fo
r p
er
so
na
l u
se
 o
nl
y.
among patients receiving axitinib was 40.1%. As regards high
grade (grade 3 or grade 4) hypertension, it was associated with
significant morbidity, leading to dose reduction or discontin-
uation of axitinib. All the ten trials showed a mean incidence
of high grade hypertension of 13.1% among those patients
assuming axitinib. To investigate the role of axitinib in the
development of hypertension and exclude the influence of
other factors such as underlying malignancy, the authors cal-
culated the RR of axitinib-induced hypertension. Treatment
with axitinib increased the risk of developing all-grade hyper-
tension, RR was 3.00. As regards high grade hypertension, RR
was 1.71 [64].
In a recent randomized, open-label, Phase III trial by
Hutson et al., the most frequent all-grade, all-causality cardio-
vascular adverse event with axitinib was hypertension. The
most frequently reported grade 3 or grade 4 cardiovascular
adverse events were hypertension and asthenia in axitinib-
treated patients. All-grade hypertension had an incidence of
49% (in 92 patients), while grade 3 hypertension had an inci-
dence of 13% (25 patients) and grade 4 < 1% (1 patient). As
regards asthenia, the incidence was 21% (39 patients) for all
grades, 7% (13 patients) for grade 3 and 2% (3 patients) for
grade 4. The most common all-causality serious cardiovascu-
lar adverse events were pleural effusion 2% (3 patients) and
cardiac arrest 2% (3 patients) in the 189 patients in the
axitinib-treated patients. Serious treatment-related adverse
events included atrial flutter, cardiac arrest, MI, asthenia,
aorto-duodenal fistula and hypertensive crisis < 1% each
(1 patient). Besides, 1 patient in the axitinib group died of
treatment-related cardiac arrest [65].
4.6 Regorafenib
Regorafenib (BAY 73-4506) is an oral multikinase inhibitor
targeting angiogenic, stromal and oncogenic RTKs with
potent antitumor activity. It potently inhibits various sets of
kinases, including the angiogenic and stromal RTKs
VEGFR1-3, TIE2, FGFR1 and PDGFR-b, which promote
tumor neovascularization, vessel stabilization and lymphatic
vessel formation and play an important role in the tumor
microenvironment. They all contribute to tumor develop-
ment and metastasis formation. Regorafenib also inhibits the
oncogenic RTKs, KIT and RET, along with the intracellular
signaling kinases c-RAF/RAF-1, BRAF and its V600E mutant
form [66]. Regorafenib was approved for advanced GIST that
cannot be surgically removed and no longer responds to ima-
tinib and sunitinib, and for previously treated metastatic colo-
rectal cancer [67-69].
In the GRID trial, an international, multicenter, prospec-
tive, randomized, placebo-controlled, Phase III trial, regorafe-
nib has been studied in patients affected by advanced GISTs
which failed to respond to imatinib and sunitinib. In this
study, 240 patients were screened and 199 were randomized
to receive regorafenib (133 patients) or placebo. The most
commonly reported regorafenib-related adverse events of
grade 3 or higher was hypertension. It was present in 31 of
132 patients (23.5%), and similar to other therapies target-
ing the VEGF/VEGFR pathway, is likely related to anti-
angiogenic effects. Besides, hypertension was one of the most
common drug-related adverse events of any grade in the regor-
afenib group, together with hand-foot skin reaction and diar-
rhea. Any grade hypertension was present in 64 patients
(48.5%), grade 3 hypertension in 30 patients (22.7%), while
grade 4 hypertension was reported in 1 patient (0.8%). This
adverse event could be managed with dose modification and
appropriate anti-hypertensive intervention. Grade 5 adverse
events were reported in 7 (5.3%) of the 132 patients in the
regorafenib group and in 3 (4.5%) of the 66 patients in the
placebo group. In 3 patients, the grade 5 adverse events were
considered by the investigators to be drug-related. Among
these 3 patients, 1 in the regorafenib group had cardiac
arrest [70]. Regorafenib has been studied in monotherapy in
the CORRECT (Phase III) trial involving 114 centers in
16 countries in North America, Europe, Asia and Australia.
Patients were enrolled when they had proven histological or
cytological adenocarcinoma of the colon or rectum, who pre-
viously were treated with irinotecan- and oxaliplatin-based
regimens. A total of 1,052 patients were screened in the study
and 760 patients were randomized to receive regorafenib
(505 patients) or placebo. Among these patients, 753 initiated
treatment (regorafenib = 500). Any grade hypertension was
reported in 139 among 500 patients treated with regorafenib
(28%). The most frequent regorafenib-related cardiovascular
adverse event of grade 3 was hypertension, affecting 36 patients
(7%). Grade 4 hypertension was not reported. Another car-
diovascular adverse event reported was dyspnea. Any grade
dyspnea affected 28 patients (6%). Only 1 patient had grade
3 dyspnea (< 1%), while grade 4 dyspnea, also in this case,
was not related [71,72].
5. New weapons in the fighting of cancer
and tumor angiogenesis: developing drugs
5.1 Vatalanib
Vatalanib (PTK787/ZK 222584) is an oral TKI that blocks
the signaling pathway, acting competitively on the ATP-
binding site of all three isoforms of VEGFR, VEGFR1 (Flt-
1), VEGFR2 (KDR) and VEGFR3 (Flt-4). It also inhibits
KIT and PDGFRa [73,74].
There are two important Phase III trials that studied
patients affected by metastatic colorectal adenocarcinoma.
The first one is the CONFIRM 1 trial, in which patients
were randomly assigned to receive vatalanib plus FOLFOX4
or placebo plus FOLFOX4. The cardiovascular adverse events
noticed by the authors were hypertension, which was present
in 133 patients (23.0%); pulmonary embolism, which was
present in 33 patients (5.7%); and deep vein thrombosis,
which was observed in 30 patients (5.2%). All of these adverse
events were grade 3 or grade 4. The most notable differences
between the vatalanib group and the placebo group were for
hypertension (23.0 vs 6.8%, respectively) and pulmonary
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embolism (5.7 vs 1.7%, respectively) [75]. In the sister trial
CONFIRM 2, 949 patients were screened and 855 patients
were randomly assigned to receive vatalanib plus FOLFOX4
or placebo plus FOLFOX4. The recruited patients had previ-
ously treated mCRC, whose disease had recurred or pro-
gressed during or within 6 months of treatment with
irinotecan in combination with a fluoropyrimidine. A higher
percentage of patients in the vatalanib group than the placebo
group experienced grade 3 or grade 4 hypertension, deep vein
thrombosis, pulmonary embolism and thromboembolic
events. Likewise, all-grade thromboembolisms. All-grade
hypertension was present in 123 patients (29.1%), and
92 patients had grade 3 or grade 4 hypertension (21.8%). It
was managed with vasodilation therapy. All-grade asthenia
was also observed; it was present in 110 patients (26.1%),
30 patients had grade 3 or grade 4 asthenia (7.1%) [76].
Further trials have been conducted over the past years.
A Phase II trial studied the use of vatalanib administered
orally, daily, as second-line monotherapy in relapsed or docu-
mented progressing patients refractory to one prior first-line
platinum-based chemotherapy or combined chemo-radio-
therapy regimen, with proven stage IIIB or IV NSCLC. The
authors noticed all-grade asthenia in 19%, and among these,
grade 1 -- 2 asthenia was present in 17% and grade 3 asthenia
in 2%. As regards all-grade hypertension, it was present in
16%, grade 1 -- 2 hypertension in 4% and grade 3 in 12%.
Instead, pulmonary embolism showed lower percentages,
with all grades being present in 5%, mainly grade 4. Addition-
ally, two patients in the study died, possibly due to treatment-
related pulmonary hemorrhage [77]. An open-label, Phase II,
multicenter trial investigated the efficacy and tolerability of
vatalanib in patients with metastatic or advanced pancreatic
cancer who failed first-line gemcitabine-based therapy. The
most common adverse events were grade 3 or grade 4, which
included hypertension. It was reported in 20% [78].
5.2 Nintedanib
Nintedanib (BIBF 1120) is a new, potent, orally assumed tri-
ple angiokinase inhibitor. It can specifically inhibit all sub-
types of VEGF, FGF and PDGFRa and b, together with
RET and FLT3. It has an acceptable general safety profile,
rare reports of hypertension or thromboembolic events and
is usually well tolerated. Nintedanib is currently under inves-
tigation for the treatment of several solid tumor types, and
among these, there are RCC, HCC, ovarian/endometrial can-
cer, lung cancer, breast cancer, prostate cancer, gliomas and
colorectal cancer, due to its good tolerability. In a Phase II
study, the efficacy and safety of nintedanib in comparison
with sunitinib in patients with advanced RCC was evaluated.
Nintedanib did not have a clinically significant effect on
QTcF or uncorrected QT interval. Besides, it was not
reported adverse events linked to the cardiovascular system.
Patients did not develop adverse events that led to dose reduc-
tion or discontinuation of the drug; besides, no deaths were
reported in association with drug-related serious adverse
events [79]. Nintedanib has been studied as a single agent,
but also in combination with standard chemotherapeutic reg-
imens. It was used in combination with pemetrexed to treat
recurrent or advanced NSCLC patients previously treated
with at least one line of platinum-based therapy or in combi-
nation with carboplatin/paclitaxel in patients with untreated
advanced NSCLC. The only reported cardiac adverse event
was hypertension, grade 1 or grade 2, in 15.4% of the
patients. The toxicities of this agent are apparently acceptable,
though the number of patients included in the Phase I and
Phase II trials is still too small to obtain meaningful results
about efficacy and safety [80,81]. It was also studied in a
Phase II trial of maintenance therapy after chemotherapy for
relapsed ovarian cancer by Ledermann et al. In this trial the
authors observed only deep vein thrombosis (1 patient) and
hypertension, grade 3 hypertension in 4.6%. Hypertension
is unusual with nintedanib, whether used alone or in combi-
nation with chemotherapy [82].
Recently, Reck et al. published data from a Phase III trial
called LUME-Lung 1. They studied and compared 655
patients treated with docetaxel plus nintedanib versus 659
who received docetaxel plus placebo. These patients were pre-
viously treated with one previous chemotherapy regimen for
NSCLC, which was histologically or cytologically confirmed
stage IIIB/IV recurrent (all histologies). Particularly, data
showed that there was a low incidence of cardiovascular side-
effects associated with anti-angiogenic agents, such as hyper-
tension or thromboembolism, which have been noted in
patients treated with other anti-angiogenic agents in NSCLC.
The authors reported some data about asthenia. All-grade
asthenia was present in 58 patients among those treated with
docetaxel plus nintedanib (8.9%), grade 1 -- 2 asthenia was
present in 43 patients (6.6%), grade 3 in 13 patients (2.0%),
while grade 5 was present in only 2 (0.3%). Chest pain was
also reported. All-grade chest pain was present in 56 patients
(8.6%), grade 1 -- 2 in 46 (7.1%), grade 3 in 4 (0.6%), grade
4 in 3 (0.5%) and grade 5 in 2 patients (0.3%), although it is
necessary to underline that asthenia and chest pain are symp-
toms attributable to various causes [83].
6. Expert opinion
Nowadays, the increasing use of anti-angiogenic drugs target-
ing TKIs enlightened the problem of cardiotoxicity. As
emerged from clinical trials, it has a large role in the treatment
of cancer patients, namely, for hypertension. It may affect
treatment efficacy because of drug interruption. Generally,
the incidence and severity of cardiovascular adverse events
are related to the underlying cardiovascular risk of the patient.
Patients with preexisting hypertension, diabetes, renal disease
and prior cardiovascular disease have the highest risk. Hence,
optimization of cardiovascular pharmacology is warranted
prior to and early in the use of VEGF signaling pathway
inhibitors. The role of hypertension as a biomarker for anti-
angiogenic drug efficacy is under discussion. Rini et al. found
G. Bronte et al.
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that patients with metastatic RCC treated with sunitinib
who developed hypertension had better outcomes. They
also observed a low incidence of hypertension-related
adverse events. If the possibility of using hypertension as
an effective biomarker is interesting, on the other hand, these
associations also raise the concern that hypertension treat-
ment may somehow limit the efficacy of TKIs. Based on
data from animal models, in which anti-angiogenic drugs
were used concomitantly with anti-hypertensive drugs, the
treatment of hypertension does not appear to limit antitumor
efficacy [16]. Finally, the development of microembolism as an
additional cause of cardiac damage cannot be entirely
excluded. Therefore, concomitant antithrombotic treatment
may be required. This is supported by the findings of myocar-
dial necrosis in the presence of normal coronary arteries,
conduction disturbances, which possibly arise from embolism
of the atrioventricular nodal artery and the occurrence of non-
cardiac vascular events [45]. To date many studies have been
conducted to analyze the mechanisms underlying the devel-
opment of cardiotoxicity, but more should be carried out,
aiming to focus on the best cardiology management of this
type of toxicity. Oncologists should avoid cancer treatment
optimizing cardiologic therapy. For this purpose, new clinical
trials should be designed to address cardiac toxicity manage-
ment. For example, two groups of patients assuming the
same anti-angiogenic drug, with different dosages, could be
compared for cardiotoxicity incidence. Furthermore, it
emerges from some studies that the developing drugs seem
to be less cardiotoxic than the older ones, especially as regards
nintedanib. The data about hypertension confirm this pat-
tern. On the other hand, although comprehensive data on
heart failure are missing, there is information on symptoms
related to systolic dysfunction that is quite heterogeneous.
A notation should be done about sorafenib because, if on
one hand, low percentage of mean all-grade hypertension is
registered, on the other hand, it determines a prolongation
of the QT/QTc interval, exposing the patient to an increased
risk of ventricular arrhythmias (Table 2).
Anti-angiogenic TKIs should be compared with bevacizu-
mab, which became part of the daily clinical practice. The
data from clinical trials, though miscellaneous, suggest that
hypertension is induced with bevacizumab in about 30% on
average, showing similar values to sunitinib and pazopanib.
A negative element for bevacizumab is the incidence of
thromboembolic events, which is definitely higher (about
19%) than the incidence registered for anti-angiogenic
TKIs, which is very low [84-86].
Some other molecules have been generating interest in the
past years, which are selective for VEGFR2 rather than target-
ing all VEGFR isoforms. The aim of these molecules is to
overcome the limitations and especially the side-effects of the
previous molecules. Among these drugs, there are small inhib-
itors that are promising, but data are still limited and informa-
tion from Phase III trials is lacking. Other molecules
generating interest are new monoclonal antibodies that target
specifically VEGFR2. Ramucirumab is an example; it is a fully
humanized IgG1monoclonal antibody that blocks the isoform
2 of the receptor. Data from Phase III trials, REGARD and
RAINBOW, showed the hypertensive effect of this drug.
The frequency of hypertension in the population was similar
to the mean value registered for nintedanib (~ 15%) [87-91].
Another important aspect is the monitoring of the develop-
ment of cardiac adverse events during oncological treatment.
The use of predictive biomarkers for cardiotoxicity could
play a key role in it. Physicians could benefit from the use
of laboratory biomarkers such as TnI, NTproBNP and the
analysis of fragments of genetic material such as miRNA.
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Table 2. Mean all grades of each side-effect linked to cardiotoxicity of the anti-VEGFR TKIs.
Drug Side effect (mean all grades)
Hypertension Cardiac
ischemia/
infarction
Arterial
thromboembolic
events
QT prolongation/ECG
changes
Congestive heart
failure and/or symptoms
related (e.g., asthenia,
dyspnea)
Sorafenib ~ 11.3% ~ 3.8% ~ 1.7% ~ 40.5% ~ 1%
Sunitinib ~ 34.3% -- -- ~ 50%
Pazopanib ~ 35.9% ~ 2% ~ 3% < 2% ~ 7%
Vandetanib ~ 24.2% -- -- ~ 18% ~ 21%
Axitinib ~ 43% < 1 % -- < 1% 21%
Regorafenib ~ 38.3% -- -- -- 6%
Vatalanib ~ 22.7% -- -- -- ~ 22.6%
Nintedanib 15.4% -- Rare No clinically significant effect ~ 8.7%
TKIs: Tyrosine kinase inhibitors.
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